A.G.P. Maintains Buy Rating on Imunon, Adjusts Price Target
Analyst firm A.G.P. has maintained its 'Buy' rating on Imunon, Inc. while lowering its price target for the company's stock to $6.
Stocks · News reference
Imunon, Inc. presented new translational data from its Phase 2 OVATION 2 study of IMNN-001 for advanced ovarian cancer at the SITC 2026 annual meeting.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analyst firm A.G.P. has maintained its 'Buy' rating on Imunon, Inc. while lowering its price target for the company's stock to $6.
Imunon, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical development programs, including the Phase 3 trial for IMNN-001.
Filed: 2026-11-12 AccNo: 0001493152-26-051202 Size: 366 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
IMUNON announced new translational data from its Phase 2 OVATION 2 study showing that IMNN-001, when combined with standard chemotherapy, increased anti-tumor T-cell activity and improved median overall survival by 14.7 months in advanced ovarian cancer patients. The data demonstrates the drug's mechanism of converting the tumor microenvironment from immunologically 'cold' to 'hot,' supporting the ongoing Phase 3 OVATION 3 trial.
Imunon, Inc. announced it will host a conference call on November 12, 2026, to discuss its financial results for the third quarter ended September 30, 2026, and provide updates on its clinical development programs.
Imunon, Inc. has announced an agreement to divest its rights to ThermoDox®, a heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics, Inc.